Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Polypeptide, nucleic acid for coding polypeptide, polypeptide-modified T lymphocyte and application of T lymphocyte

A technology of lymphocytes and B lymphocytes, applied in the biological field, can solve the problems of general curative effect, adverse reactions, high toxicity, etc., and achieve the effect of effectively treating solid tumors

Active Publication Date: 2018-03-23
HEBEI SENLANG BIOTECH CO LTD
View PDF1 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, immunotherapy also shows certain adverse reactions, especially the compound combination, some combinations are too toxic but the curative effect is mediocre

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide, nucleic acid for coding polypeptide, polypeptide-modified T lymphocyte and application of T lymphocyte
  • Polypeptide, nucleic acid for coding polypeptide, polypeptide-modified T lymphocyte and application of T lymphocyte
  • Polypeptide, nucleic acid for coding polypeptide, polypeptide-modified T lymphocyte and application of T lymphocyte

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Example 1, construction of CAR(CD30)-CAR(CD22)-aPDL1 lentiviral vector

[0069] The inventors designed three target gene structures according to genetic engineering technology, and their sequences were sequentially spliced ​​from the amino terminal to the carboxyl terminal as follows:

[0070] 1. CAR(CD30):ScFv(CD30)-Hinge(CD8)-TM(CD8)-CD137-CD3ζ

[0071] 2. CAR(CD22):ScFv(CD22)-Hinge(IgG4-short)-TM(CD28)-CD137-CD3ζ

[0072] 3. CAR(CD30)-CAR(CD22)-aPDL1:

[0073] ScFv(CD30)-Hinge(CD8)-TM(CD8)-CD137-CD3ζ-T2A-ScFv(CD22)-Hinge(IgG4-short)-TM(CD28)-CD137-CD3ζ-P2A-ScFv(PD-L1) .

[0074] Among them, ScFv(CD30)-Hinge(CD8)-TM(CD8)-CD137-CD3ζ expresses a chimeric antigen receptor targeting CD30, and its gene sequence is as follows: CD30 antibody single-chain variable region, CD8a hinge Region and transmembrane region, CD137 signal domain, CD3ζ chain intracellular region. The above sequence targets the antigen chimeric receptor sequence of CD22 in series through the self-cle...

Embodiment 2

[0081] Embodiment 2, lentiviral packaging

[0082] The operation steps of packaging are as follows:

[0083] The 293FT cell culture flask (T175) that had grown to 80%-90% was cooled from 37°C in 5% CO 2 Take it out from the cell culture incubator, add 2 mL of EDTA-free-0.25% Trypsin to digest, collect and wash the cells, add 4.5×10 per 10 cm cell culture dish 6 For each cell, add 9mL DMEM medium, shake gently, put in 37℃5%CO 2 cultured in an incubator.

[0084] On day 2, 500 μL per plate Buffer, 6 μg target gene, 3 μg psPAX2, 1.5 μg pMD2.G, mix the above solutions evenly. Add to the mixture 25μL / 10cm plate, mix well again, and let stand at room temperature for 10min. Warm the 293FT cells used for packaging virus from 37°C 5% CO 2 Take it out of the cell culture incubator, add the above mixture evenly to each plate, shake gently, and put it in 37°C 5% CO 2 in the incubator. After 4 hours, discard the old medium, add 10mL of preheated PBS to wash the cells, then add 9...

Embodiment 3

[0086] Example 3, preparation of CAR-T cells

[0087] 1. Cell expansion (Day0)

[0088] Aseptically collect 50-100ml of venous blood from the patient, and perform density gradient centrifugation on the blood sample to obtain peripheral blood mononuclear cells (PBMC). CD3+ cells were sorted with CD3 sorting magnetic beads (Miltenyi, Germany). The sorted positive cells were first resuspended with 2ml of medium, and T cell activation magnetic beads (Gibco, USA) were added according to the ratio of positive cells to magnetic beads at 1:1. Then spread a 24-well plate according to 3×10^5 cells / 500 μl medium / well, and move to 37°C, 5% CO 2 The cells were cultured in an incubator for 2 days.

[0089] 2. Cell transfection (Day2)

[0090] The 24-well plate was taken out of the incubator in advance and placed in a biological safety cabinet, and allowed to cool to room temperature. Then add Protamine Sulfate according to 1‰ (V / V). After the virus was melted, it was added to the 24-w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and discloses a polypeptide containing two chimeric antigen receptor structures, nucleic acid for coding the polypeptide, a modified T lymphocyte, and a preparation method and application of the T lymphocyte. The polypeptide provided by the invention contains the two chimeric antigen receptor (CAR) structures, wherein one chimeric antigen receptor structure specifically targets a tumor cell, and the other one specifically targets a normal B lymphocyte, so that a CAR-T cell is effectively amplified through recognizing the B lymphocyte ofa blood circulation system, and more CAR-T cells arrive at a solid tumor part so as to specifically kill the tumor cell for improving a treatment effect on the solid tumor. The polypeptide further comprises an ScFv structure of an anti-PD-L1 monoclonal antibody, and the CAR-T cells can simultaneously secrete a PD-L1 monoclonal antibody which interdicts an immunosuppressive action medicated by a PD1 / PDL1 signal pathway and T cell failure, so that the treatment effect on the solid tumor is improved, the functional activity of immune cells in vivo is prolonged at the same time, and finally the tumor recurrence is retarded and even avoided.

Description

[0001] This application requires a Chinese patent application submitted to the China Patent Office on October 30, 2017, with the application number 201711034769.5, and the title of the invention is "a polypeptide, a nucleic acid encoding it, T lymphocytes modified by it, and its preparation method and application" priority, the entire contents of which are incorporated in this application by reference. technical field [0002] The invention belongs to the field of biotechnology, and relates to a polypeptide, a nucleic acid encoding it, a modified T lymphocyte and its preparation method and application, in particular to a polypeptide comprising two chimeric antigen receptor structures, a nucleic acid encoding it, and its Modified T lymphocyte and its preparation method and application. Background technique [0003] After entering the 21st century, with breakthroughs in the two major technical fields of adoptive cell therapy represented by CAR-T and immune checkpoint inhibitor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N7/01C12N5/10A61K35/17A61P35/00G01N33/68
CPCA61K35/17C07K16/2803C07K16/2827C07K16/2851C07K16/2863C07K16/2866C07K16/2878C07K16/2896C07K16/3084C07K16/32C07K2317/53C07K2317/622C12N5/0636C12N15/86C12N2509/00C12N2510/00C12N2740/15043G01N33/6854
Inventor 李建强
Owner HEBEI SENLANG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com